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Two expression vectors were constructed to produce a putative mature a-pokeweed antiviral protein (a-PAP) in Excherichiu co/i with its NH,- and 
COOH-terminal extrapeptides excised. One was for its intracellular expression with a methionine at its NH?-terminal. The other was for its secretion 
using an ompA signal peptide. The former product was purified from the total soluble proteins of the transformant with a yield of 1.74 mg/liter 
and the latter had a yield of 5.55 mg/liter. Both products exhibited RNA N-glycosidase activity on wheat ribosomes and inhibitory activity to protein 
synthesis in a rabbit reticulocyte system. 
a-Pokeweed antiviral protein; Expression: RNA N-glycosidase activity 
1. INTRODUCTION 
Many, and possibly all, plants contain ribosome-in- 
activating proteins (RIPS) [1], e.g. ricin from Ricinus 
communis [2], a-trichosanthin from Trichosanthes kiri- 
lowii Maxim. [3], and Miruhilis antiviral protein (MAP) 
from Mirabilis jufapa L. [4]. It has been indicated that 
RIPS cleave the N-glycosidic bond at adenine4”14 of rat 
liver 28s rRNA with their RNA N-glycosidase activity 
to inactivate the ribosomes, resulting in the inhibition 
of protein synthesis [5,6]. Pokeweed antiviral protein 
(PAP) is an RIP isolated from several organs of 
Phytolucca americana [7-91. It inhibits not only infec- 
tion by plant viruses [S,lO,l 11, but also the replication 
of mammalian viruses including Type 1 human immu- 
nodeficiency virus [lo,1 2-l 51. Thus, PAP has attracted 
the interest of many researchers for its possible use as 
a therapeutic agent. 
We have previously reported the nucleotide sequence 
of the genomic gene for a-PAP and its expression in 
Escherichia coli [16]. The gene product depurinated 
wheat ribosomes, indicating that it is a functional pro- 
tein exhibiting RNA N-glycosidase activity [16]. How- 
ever, the protein was obtained from the total soluble 
proteins of the transformant with a very low yield of 30 
yglliter. A comparison of its amino acid sequence to 
that of native PAP from the seeds suggested that it could 
exert its RNA N-glycosidase activity without putative 
NH,- and COOH-terminal extrapeptides [ 161. There- 
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fore, two expression vectors were constructed to pro- 
duce a putative mature a-PAP in E. coli. Here we report 
the substantial expression of the protein with undimin- 
ished activity. 
2. MATERIALS AND METHODS 
2. I Materials 
Restriction endonucleases and DNA modification enzymes were 
purchased from Takard Shuzo (Kyoto, Japan) and Bethesda Research 
Laboratory (Tokyo, Japan). CM-Sepharose, Blue-Sepharose and 
Mono-S columns were from Pharmacia LKB (Tokyo, Japan). Wheat 
germ extract. rabbit reticulocyte lysate and L-[?S]methionine were 
from Amersham (Tokyo, Japan). 
2.2. Mod$icution of’un a-PAP gmomic gene hy PCR 
PCR primers were synthesized using a 392 DNA/RNA Synthesizer 
(Applied Biosystems Inc.). PCR was carried out in the conventional 
way using a GeneAmp PCR Reagent Kit and a DNA Thermal Cycler 
(Takara Shuzo). Template DNA constitues 10 ng of the genomic gene 
in EMBL3 [16]. The nucleotide sequences of PCR products were 
determined using a T’Sequencing Kit (Pharmacia) after cloning in 
pBluescript (Stratagene). The expression vector pSHompA was a de- 
rivative of pSH7 [17] with the P, promoter and (1857 repressor re- 
placed by fuc and lucI9. respectively [16]. 
2.3. Expression a d pur$cution of LI rrcornhinunt muture a-PAP 
The E. coti strain MM294 [I 71 was transformed using each expres- 
sion vector. An overnight culture of each transformant (50 ml) was 
incubated in 1 liter of LBroth at 37°C for 3 h. After the addition of 
IPTG to a final concentration of 0.1 mM. culture was continued for 
3 h. Cells were harvested by centrifugation and then ruptured. After 
removal of the insoluble precipitate by 30% saturation with 
(NH&SO,. the protein was purified through CM-Sepharose, Blue- 
Sepharose and Mono-S column chromatography as described previ- 
ously [4,17]. The NH?-terminal peptide sequence of each protein was 
determined with a 477A Protein Sequencer (Applied Biosystems Inc.) 
using automatic Edman degradation [17]. The protein in the culture 
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Fig. 1. Schematic diagrams of expression vectors for aPAP-E and 
aPAP-S. Thin arrows indicate the directions of the PCR primers PE, 
PS and PC. Np and Cp denote the putative NHL- and COOH-terminal 
extrapeptides of a-PAP [16], respectively. tuc and oA indicate IUC 
promoter and ompA signal peptide. respectively. N, N&I: X. XbaI; 
and H. HindIII. 
medium was precipitated with 90% (NH&SO, and purified through 
the same column chromatography procedures. 
2.4. RNA N-glyosidase uctivity of a recombinant mature r-PAP and 
its inhibitory uctivity to in vitro protein synthesis 
The RNA N-glycosidase activity of the protein was assayed using 
wheat germ extract. Removal of the specific adenine from the ribo- 
somes was analyzed by a primer extension procedure using the primer 
5’-TTCGCGCCACTGGCTTT-3’, which is complementary to the re- 
gion 4460 bases downstream from the adenine attacked by RIPS in 
wheat 25s rRNA [18] as described previously [16,19]. 
The inhibitory activity of the protein to protein synthesis was meas- 
ured using a rabbit reticulocyte system as described previously [17]. 
Cucumber mosaic virus RNA or Brome mosaic virus RNA was used 
as template mRNA. MAP was the positive control [ 171. 
3. RESULTS 
The PCR primers PE, PS and PC were synthesized to 
modify the u-PAP genomic gene. Primer PE (5’- 
CCCCATATGATAAATACAATCACCTTCGAT-3’) 
was designed to replace the NH,-extrapeptide with a 
methionine and create an N&I site. Primer 
PS (5’-GGGCATATGACTCTAGAATAAATACAA- 
TCACCTTCGAT-3’) was designed to excise the 
extrapeptide and create an X&I site. Primer 
PC (5’-GGGGAAGCTTCATTAAGTTGCCTGGCA- 
GGTCCC-3’) was designed to replace the COOH-ex- 
trapeptide with two stop codons and create an Hind111 
site (Fig. 1). The PCR product from PE and PC (crPAP- 
E gene) was digested with N&I and HindIII, and then 
inserted in the corresponding sites of pSHompA for the 
intracellular expression of the putative mature a-PAP. 
The PCR product from PS and PC was digested with 
Hind111 and XbaI, and then inserted in the correspond- 
ing sites of pSHompA to create a chimeric gene combin- 
ing an ompA signal peptide and the putative mature 
E-PAP (aPAP-S gene) with a linker peptide (APTLE) 
between them for the secretion of the protein (Fig. 1). 
Each expression vector was introduced into the E. 
coli strain MM294 [17, 201. The fresh weights of the 
transformants expressing aPAP-E and aPAP-S were 
2.71 g/liter and 2.19 g/liter, respectively, when cultured 
without IPTG, and 1.75 g/liter and 1.32 g/liter, respec- 
tively, when cultured with IPTG for the expression of 
the genes. aPAP-E and aPAP-S were extracted from the 
total soluble proteins of whole transformants. aPAP-S 
was also extracted from the culture medium. The pro- 
teins purified through CM-Sepharose and Blue-Sepha- 
rose column chromatography were analyzed on 15% 
SDS-PAGE (Fig. 2). Large amounts of clPAP-E and 
aPAP-S were recovered from whole transformants 
(lanes 1 and 2) while only a trace level of aPAP-S was 
found in the culture medium (lane 3). The proteins from 
the whole transformants were further purified to homo- 
geneity by Mono-S column chromatography. The final 
yields of aPAP-E and clPAP-S were 1.74 mg/liter and 
5.55 mg/liter, respectively. The NHz-terminal peptide 
sequence of aPAP-E was ‘MINTITFDVGNATIN- 
KYATFMKSIHNQA’, which is identical to that of the 
putative mature a-PAP except for the first methionine 
42 
30 
20 
14 
1 2 3 
Fig. 2. aPAP-E and aPAP-S purified through CM-Sepharose and 
Blue-Sepharose column chromatography. 4 ~1 of each sample (5 ml) 
was analyzed on 15% SDS-PAGE. Lane 1: aPAP-E from total soluble 
proteins of the transformant. Lane 2: aPAP-S from total soluble 
proteins of the transformant. Lane 3: zPAP-S from a culture medium 
of the transformant. An arrow indicates the position of aPAP-E and 
aPAP-S. 
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Fig. 3. RNA N-glycosidase activity of aPAP-E and aPAP-S on wheat 
ribosomes. An arrowhead indicates the extended primer terminated 
after the addition of 43 nucleotides. MAP denotes Mirahilis antiviral 
protein as a positive control [17]. 
introduced by the PCR. The NHz-terminal peptide se- 
quence of aPAP-S was ‘APTLEINTITFDVGNA 
TINKYATFMKSI-HN’. It indicates that the ompA 
signal peptide was cleaved from aPAP-S and only a 
linker peptide (APTLE) was retained in the protein at 
its NH,-terminal. 
The RNA N-glycosidase activity of aPAP-E and 
aPAP-S was assayed by the primer extension procedure 
using wheat germ extract [16.19]. The target adenine 
was specifically removed from the ribosomes by both 
proteins (Fig. 3) as reported previously [16]. The radio- 
activity of the bands from ribosomes treated with either 
aPAP-E or aPAP-S at a concentration of 10 pM (lanes 
4 and 5) was far stronger than that treated with MAP 
at the same concentration (lane 6). These data indicate 
that the proteins have the RNA N-glycosidase activity 
specific to RIPS and that their activity is stronger than 
that of MAP. The inhibitory activity of both proteins 
to in vitro protein synthesis was measured using a rabbit 
reticulocyte system (Fig. 4). In this experiment, the me- 
dian inhibitory concentrations of L-[35S]methionine in- 
corporation of aPAP-E and aPAP-S were 0.007 and 
0.005 nM, respectively, whereas that of MAP was 0.09 
nM. These results indicate that both recombinant pro- 
teins have an inhibitory activity at least 12 times as high 
as MAP. 
4. DISCUSSION 
We have previously reported the trace level expres- 
sion (30 mg/liter) of a-PAP with the putative extrapep- 
tides [16]. The present study shows that a substantial 
amount of the putative mature a-PAP without ex- 
trapeptides can be produced by E. coli while maintain- 
ing its activity. We speculate that the putative NH?- 
terminal extrapeptide, which contains many methionine 
and valine residues [ 161, might make efficient expression 
difficult and/or the putative COOH-terminal extrapep- 
tide might make the protein susceptible to endogenous 
proteases in E. coli. 
The inhibitory activity of native PAPS from the leaves 
and seeds to in vitro protein synthesis was reported to 
be about 8 and 54 times higher than that of MAP, 
respectively [l, 171. Since aPAP-E and aPAP-S were at 
least 12 times as active as MAP on rabbit ribosomes, 
both recombinant proteins were concluded to have an 
inhibitory activity comparable with that of the native 
PAPS. 
The transformant expressing aPAP-S was too sticky 
and weak to fractionate periplasmic proteins by the 
osmotic shock method [21]. aPAP-S was mainly recov- 
ered from the soluble proteins of whole transformant, 
and only a slight amount was obtained from the culture 
medium. The NH,-terminal sequence of aPAP-S re- 
vealed that the ompA signal peptide was cleaved from 
the chimeric protein, probably during secretion. There- 
fore, aPAP-S seems to have been secreted into the 
periplasmic space of the transformant. 
It has been reported that E. cofi 23s rRNA is slightly 
depurinated by native PAPS [22]. aPAP-S secreted into 
the periplasmic space could not depurinate ribosomes 
of the transformant, in contrast to aPAP-E expressed 
intracellularly. This might be the reason why about 3 
times more aPAP-S was produced in E. coli than aPAP- 
l : aPAP-E 
n : aPAP-S 
o:MAP 
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Fig. 4. Inhibitory activity of zPAP-E and aPAP-S on in vitro protein 
synthesis in a rabbit reticulocyte system. Closed circles and boxes 
indicate aPAP-E and aPAP-S, respectively. Open circles indicate 
MAP as a positive control [17]. The incorporation of L-[i’S]methionine 
is presented relative to that with (100%) and without (0%) template 
mRNA. 
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E in spite of the lower cell yield of the aPAP-S transfor- 
mant than of the olPAP-E transformant. 
aPAP-S and aPAP-E were produced in substantial 
amounts by E. coli as functionally active forms in the 
present experiment, even though it has been reported 
that some researchers encountered difficulty in express- 
ing PAP in E. coli [22]. Therefore the putative mature 
a-PAP seems to be a suitable form for obtaining a poke- 
weed antiviral protein by genetic engineering for practi- 
cal use such as a therapeutic agent. 
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